HLI373 is a potent Hdm2 (MDM2) inhibitor that suppresses Hdm2 ubiquitin E3 ligase activity, thereby stabilizing p53 and inducing apoptosis in tumor cells harboring wild-type p53; it exhibits antimalarial activity against both chloroquine-sensitive (PfD6) and chloroquine-resistant (PfW2) strains of Plasmodium falciparum.